Company news
Gain Therapeutics, Inc. news in 2023
Gain Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 3, 2023
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
November 30, 2023
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 28, 2023
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
November 23, 2023
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
November 20, 2023
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 13, 2023
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
October 3, 2023
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
September 24, 2023
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
September 19, 2023
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
September 11, 2023
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
August 27, 2023
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 9, 2023
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 6, 2023
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
July 30, 2023
Gain Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 11, 2023
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 2, 2023
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 11, 2023
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 28, 2023
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 22, 2023
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 21, 2023
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 20, 2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 8, 2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
February 26, 2023
Decks in 2023
- Investor Presentation (October 2023)
Investor deck · 19 slides · Oct 18, 2023
- Investor Presentation (2023)
Investor deck · 22 slides · 2023